CTOs on the Move

Axion Pharmaceuticals

www.jaspercapital.com

 
Axion Pharmaceuticals is a South San Francisco, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $10-50 Million
  • www.jaspercapital.com
  • 395 Oyster Point Blvd Ste 405
    South San Francisco, CA USA 94080
  • Phone: 650.906.4450

Executives

Name Title Contact Details

Similar Companies

New England Peptide

New England Peptide is a Gardner, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Strateos

Strateos is a pioneer in the development of remote access laboratories and lab control software for life science discovery.

PhaseBio

PhaseBio is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies to treat orphan diseases, with an initial focus on cardiopulmonary indications. Our lead product candidate is PB2452, a novel reversal agent for the antiplatelet drug ticagrelor, and our second product candidate is PB1046, a once-weekly fusion protein for the treatment of pulmonary arterial hypertension. PB1046 utilizes our elastin-like polypeptide technology, which also serves as the engine for our preclinical pipeline. Our proprietary technology platform uses recombinant elastin-like polypeptide (ELP) biopolymers to control the half-life, bioavailability and physical characteristics of molecules for ease of administration. The compounds are engineered for a specific rate of absorption to enhance efficacy and reduce side effects, which may lead to less-frequent dosing and better patient compliance. PB1046 is a vasoactive intestinal peptide (VIP) receptor agonist that leverages our ELP technology for once-weekly dosing. PB1046 is being evaluated in clinical studies in pulmonary arterial hypertension (PAH) and in preclinical studies for the treatment of cardiomyopathy associated with dystrophinopathies. PhaseBio recently concluded a Phase 2a trial of PB1046 in patients with heart failure with reduced ejection fraction. We are also evaluating our development candidate PB2452, a reversal agent for the antiplatelet therapy ticagrelor, in clinical trials. PB2452 was exclusively licensed from MedImmune, the global biologics research and development arm of AstraZeneca, for global development and commercialization by PhaseBio. PhaseBio continues to explore opportunities to apply our ELP biopolymer technology to compounds that may benefit from its unique properties. We are privately owned, with headquarters and research laboratories in Malvern, PA.

Semler Research Center Pvt.

Semler Research Center Pvt. is a North Hollywood, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Du Pont Pharmaceuticals Co

Du Pont Pharmaceuticals Co is a Wilmington, DE-based company in the Healthcare, Pharmaceuticals, and Biotech sector.